Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 308 entries
View as:

Evaluation of Thymoglobulin Induction and Reduced Doses of Calcineurin Inhibitors on Liver Transplant Rejection

Phase: N/A Priority: Normal
NCT ID: NCT00117689 Org: User:
Start: 04/30/05 End: 12/31/07 Due: 12/31/08

AMD3100 (Plerixafor) Added to a Mobilizing Regimen of Granulocyte-colony Stimulating Factor (G-CSF) to Increase the Number of Peripheral Blood Stem Cells (PBSCs) in Patients With Hodgkin's Disease

Phase: N/A Priority: Normal
NCT ID: NCT00396201 Org: User:
Start: 11/30/04 End: 01/31/08 Due: 01/31/09

Collection of Blood Samples From Patients With Relapsing MS Who Developed ITP After Receiving Lemtrada

Phase: N/A Priority: Normal
NCT ID: NCT03784898 Org: User:
Start: 02/08/19 End: 12/11/19 Due: 12/11/20

Study of Safety and Efficacy of Renagel® Compared With Calcium Acetate in Patients With Peritoneal Dialysis

Phase: N/A Priority: Normal
NCT ID: NCT00196755 Org: User:
Start: 12/31/04 End: 04/30/06 Due: 04/30/07

A Study of Two Fabrazyme (Agalsidase Beta) Dosing Regimens in Treatment-naïve, Male Pediatric Patients Without Severe Symptoms

Phase: N/A Priority: Normal
NCT ID: NCT00701415 Org: User:
Start: 09/30/08 End: 06/30/15 Due: 06/30/16

Sepraspray™ Laparoscopic Myomectomy Study

Phase: N/A Priority: Normal
NCT ID: NCT00624390 Org: User:
Start: 11/30/07 End: 12/31/08 Due: 12/31/09

Phase 2, Double-blind, Randomized, Controlled Multi-center Clinical Trial of the Safety and Efficacy of Transplanted Fetal Porcine Cells in Patients With Parkinson's Disease.

Phase: N/A Priority: Normal
NCT ID: NCT00226460 Org: User:
Start: 08/31/97 End: 01/31/01 Due: 01/31/02

Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing

Phase: N/A Priority: Normal
NCT ID: NCT00324376 Org: User:
Start: 03/31/03 End: 05/31/04 Due: 05/31/05

Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHL

Phase: N/A Priority: Normal
NCT ID: NCT00077961 Org: User:
Start: 12/31/03 End: - Due: -

Evaluate the Safety, Pharmacodynamics, Pharmacokinetics, and Exploratory Efficacy of GZ/SAR402671 in Treatment-naïve Adult Male Patients With Fabry Disease

Phase: N/A Priority: Normal
NCT ID: NCT02228460 Org: User:
Start: 11/30/14 End: 09/30/16 Due: 09/30/17

Phase II Study of Clofarabine in Pediatric Acute Myelogenous Leukemia (AML) Patients

Phase: N/A Priority: Normal
NCT ID: NCT00042354 Org: User:
Start: 05/31/02 End: 08/31/04 Due: 08/31/05

Cross-Over Study of Sevelamer Hydrochloride and Sevelamer Carbonate

Phase: N/A Priority: Normal
NCT ID: NCT00440648 Org: User:
Start: 03/31/05 End: 07/31/06 Due: 07/31/07

Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

Phase: N/A Priority: Normal
NCT ID: NCT00464321 Org: User:
Start: 05/31/07 End: 02/28/10 Due: 02/28/11

A Long-term Follow-up Study Of Multiple Sclerosis Patients Who Participated In Genzyme-sponsored Studies of GZ402668

Phase: N/A Priority: Normal
NCT ID: NCT02313285 Org: User:
Start: 01/12/15 End: 04/20/22 Due: 04/20/23

A Study to Compare the Safety and Effectiveness of a Non-FDA Approved Device Dermal Gel Extra (DGE) and an FDA Approved Device for the Correction of Nasolabial Folds (NLFs)

Phase: N/A Priority: Normal
NCT ID: NCT00444626 Org: User:
Start: 05/31/07 End: 07/31/08 Due: 07/31/09

A Study of Clofarabine in Combination With Etoposide and Cyclophosphamide in Children With Acute Leukemias.

Phase: N/A Priority: Normal
NCT ID: NCT00315705 Org: User:
Start: 03/31/06 End: 05/31/10 Due: 05/31/11

Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B

Phase: N/A Priority: Normal
NCT ID: NCT03974113 Org: User:
Start: 01/28/20 End: 08/01/28 Due: 08/01/29

First-in-human Study With Ascending Single Intra-articular Doses of GZ389988 in Patients With Painful Osteoarthritis of the Knee

Phase: N/A Priority: Normal
NCT ID: NCT02424942 Org: User:
Start: 04/30/15 End: 07/31/16 Due: 07/31/17

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00500292 Org: User:
Start: 03/31/07 End: 11/30/16 Due: 11/30/17

Extension Study of Long-term Safety and Efficacy of Myozyme for a Single Patient With Pompe Disease Who Were Previously Enrolled in Genzyme Sponsored ERT Studies.

Phase: N/A Priority: Normal
NCT ID: NCT00765414 Org: User:
Start: 04/30/03 End: 08/31/06 Due: 08/31/07

A Phase II, Double Blind Study of 2 Doses of ZACTIMA™(ZD6474) in Combination With FOLFIRI vs FOLFIRI Alone for the Treatment of Colorectal Cancer in Patients

Phase: N/A Priority: Normal
NCT ID: NCT00454116 Org: User:
Start: 03/31/07 End: 11/30/09 Due: 11/30/10

A Study to Evaluate the Effect of Thymoglobulin and Reduced Doses of Steroids to Prevent Renal Transplant Rejection

Phase: N/A Priority: Normal
NCT ID: NCT00089947 Org: User:
Start: 06/30/03 End: 12/31/05 Due: 12/31/06

Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT01738373 Org: User:
Start: 12/31/11 End: 11/30/12 Due: 11/30/13

This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.

Phase: N/A Priority: Normal
NCT ID: NCT00059722 Org: User:
Start: 05/31/03 End: 06/30/07 Due: 06/30/08

Safety, Pharmacokinetics (PK), And Hematological Activity Of AMD3100 (Plerixafor) In Subjects With Renal Impairment

Phase: N/A Priority: Normal
NCT ID: NCT00445302 Org: User:
Start: 01/31/06 End: 08/31/07 Due: 08/31/08